Editas Medicine (US.EDIT)
资本配置审计 · 期间： 2014 – 2026
核心指标
US.EDIT · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 100.4% | → |
| ROE | -41.0% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.15 | ↑ |
| Gross Margin | 0.0% | ↓ |
US.EDIT (Editas Medicine) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 100.4% → ROE -41.0% ↑ Cash Conversion - → D/E Ratio 0.15 ↑ Gross Margin 0.0% ↓
核心指标
US.EDIT (Editas Medicine) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 100.4% →ROE -41.0% ↑Cash Conversion - →D/E Ratio 0.15 ↑Gross Margin 0.0% ↓免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies